These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 30816327)

  • 1. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
    Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
    Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
    Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
    Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MyD88/CD40 signaling retains CAR T cells in a less differentiated state.
    Prinzing B; Schreiner P; Bell M; Fan Y; Krenciute G; Gottschalk S
    JCI Insight; 2020 Nov; 5(21):. PubMed ID: 33148882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
    Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
    Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
    Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
    Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.
    Sánchez-Moreno I; Lasarte-Cia A; Martín-Otal C; Casares N; Navarro F; Gorraiz M; Sarrión P; Hervas-Stubbs S; Jordana L; Rodriguez-Madoz JR; San Miguel J; Prosper F; Lasarte JJ; Lozano T
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38955421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.
    Qin H; Edwards JP; Zaritskaya L; Gupta A; Mu CJ; Fry TJ; Hilbert DM; LaFleur DW
    Mol Ther; 2019 Jul; 27(7):1262-1274. PubMed ID: 31043341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Cannabidiol on the Functions of Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Chantarat N; Pe KCS; Suppipat K; Vimolmangkang S; Tawinwung S
    Cannabis Cannabinoid Res; 2024 Jun; 9(3):819-829. PubMed ID: 37878339
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
    Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
    Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.